ClinicalTrials.gg

Program

c-Met Inhibitor ANS014004

Also written as “ANS014004” and “ANS014004 + PLB1004”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung, led by 2 companies.

Furthest: phase 2, since Feb 27, 20243 company-led studies, 3 open or runningNext primary completion: Apr 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Avistone Biotechnology22 open or runningphase 1since Feb 27, 2024Feb 27, 2024Apr 2027phase 1 · NCT06307795
Beijing Pearl Biotechnology Limited Liability11 open or runningphase 2since Nov 4, 2025Nov 4, 2025Dec 2029phase 2 · NCT07285148

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 27, 2024First study: phase 1 study in Locally Advanced or Metastatic Solid TumorsNew to Avistone BiotechnologyAvistone Biotechnology · NCT06328439 · 40 enrolled · China
  2. Mar 5, 2024Phase 1 study in Locally Advanced or Metastatic Solid TumorsAvistone Biotechnology · NCT06307795 · 63 planned · United States, Canada, China
  3. Nov 4, 2025Beijing Pearl Biotechnology Limited Liability’s first study: phase 2 study in Carcinoma, Non-Small-Cell LungNew to Beijing Pearl Biotechnology Limited LiabilityBeijing Pearl Biotechnology Limited Liability · NCT07285148 · 253 planned · United States

Ahead

  1. Apr 2027Primary completion: phase 1 study in Locally Advanced or Metastatic Solid TumorsAvistone Biotechnology · NCT06307795
  2. Dec 31, 2027Primary completion: phase 1 study in Locally Advanced or Metastatic Solid TumorsAvistone Biotechnology · NCT06328439
  3. Dec 2029Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungBeijing Pearl Biotechnology Limited Liability · NCT07285148

TargetBeta

MET →read by rule
“An orally bioavailable, next-generation, type II inhibitor of the oncoprotein c-Met (hepatocyte growth factor receptor; HGFR), ”NCIt, by rule

Other programs on MET

ProgramCompanyFurthest phaseStudies
cabozantinibruleExelixisphase 436
CrizotinibrulePfizerphase 431
telisotuzumab adizutecanAbbViephase 318
zanzalintinibruleExelixisphase 317
amivantamabruleJohnson & Johnsonphase 316
vebreltinibruleBeijing Pearl Biotechnology Limited Liabilityphase 39
glumetinibruleHaihe Biopharmaphase 38
vilzemetkibSino Biopharmaceuticalphase 38
dalmelitinibHansoh Pharmaceutical Groupphase 37
bafisontamabruleshanghai-epimab-biotherapeutics-co-ltdphase 35
HS-20117Hansoh Pharmaceutical Groupphase 33
SHR-1826Jiangsu HengRui Medicinephase 27

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07285148Carcinoma, Non-Small-Cell Lung · United States2Not yet recruitingBeijing Pearl Biotechnology Limited LiabilityDec 2029253
NCT06307795Locally Advanced or Metastatic Solid Tumors · United States, Canada, China1RecruitingAvistone BiotechnologyApr 202763
NCT06328439Locally Advanced or Metastatic Solid Tumors · China1Active, not recruitingAvistone BiotechnologyDec 31, 202740

How it is read

Names in the registry

  • “ANS014004”, 2 entries
  • “ANS014004 + PLB1004”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.